Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections
AssigneeMondobiotech Laboratories Anstalt
InventorDorian Bevec
Life of this patent
Estimating the term…
Abstract
The invention describes for the first time the preclinical/cellular and clinical relevance of VIP, PACAP as well as of substances with the same biological activity as VIP and PACAP for the treatment of interstitial lung infections such as idiopathic pulmonary fibrosis, hypersensitive pneumonia or diffused panbronchiolitis. VIP and PACAP are synthesised in different areas of the central nervous system, e.g. in specific cerebral areas such as the hippocampus and the cortex, as well as in the peripheral ganglia. VIP is also released by immune cells.
Claims18
Use of a substance for synthesising a drug for the treatment of patients who suffer from a pulmonary disease which is directly or indirectly associated to idiopathic pulmonary disease, hypersensitive pneumonia or diffused panbronchilitis, wherein said substance is a peptide or a polypeptide containing the following amino acid sequence:
- Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 4).
Dependencies are inferred from the claim text.